March is National Colorectal Cancer Awareness Month
Your help is needed to raise awareness, encourage screenings, and support those affected by colon and rectal cancer.
Press Release
October 26, 2017 (WASHINGTON)–VARUBI, a highly anticipated treatment for colorectal patients who suffer from delayed chemotherapy-induced nausea, has been approved by the Food and Drug Administration for delivery via one-time intravenous administration. This new way to administer VARUBI provides healthcare providers with flexibility to treat patients in a more individualized manner.
VARUBI addresses delayed nausea that can arrive 24 to 120 hours after the start of chemotherapy. If nausea is not managed aggressively, it can lead to weight loss, dehydration, and hospitalization. Quality-of-life issues are incredibly important for patients and families dealing with colorectal cancer and chemotherapy. The approval of VARUBI is good step forward in addresses some of these concerns.
For more information about VARUBI, please access:
https://globenewswire.com/news-release/2017/10/25/1153687/0/en/TESARO-Announces-U-S-FDA-Approval-of-VARUBI-IV-for-Delayed-Nausea-and-Vomiting-Associated-With-Cancer-Chemotherapy.html
Related Topics
Top resources
Lexie Haglund: Beating stage IV CRC
Discover how knowing her G12C biomarker guided Lexie’s stage IV colorectal cancer treatment — from a shock diagnosis to HIPEC surgery — and why screening, research, and self-advocacy matter.
Last updated
Colorectal Cancer Alliance State of Screening Study Reveals Potentially Fatal Attitudes & Misconceptions Among Americans
Majority of Americans say they don’t have time for colorectal cancer screening, prioritizing household chores instead of health.
Last updated
Alliance meets with leaders on Capitol Hill
The meetings are part of a broader government advocacy initiative by the Alliance to address the growing prevalence of CRC and improve patient care, advance research, and break down regulatory barriers that limit access to life-saving treatments.
Last updated